Search results
2 mar 2007 · Although memantine is approved only for AD, two double-blind studies have suggested possible beneficial effects of memantine in patients with vascular dementia (Orgogozo et al 2002; Wilcock et al 2002).
- Memantine for the Treatment of Dementia: A Review on its Current and ...
The discovery of extrasynaptic NMDARs provided a rational...
- Basic information about memantine and its treatment of Alzheimer's ...
Memantine is a noncompetitive moderate‐affinity strong...
- Memantine for Alzheimer's Disease: An Updated Systematic ... - PubMed
The meta-analyses suggest the credible efficacy and safety...
- Memantine for the Treatment of Dementia: A Review on its Current and ...
13 mar 2018 · The discovery of extrasynaptic NMDARs provided a rational and physiological explanation between physiological and excitotoxic actions of glutamate. Memantine (MEM), an antagonist of extrasynaptic NMDAR, is currently used for the treatment of AD jointly with acetylcholinesterase inhibitors.
The study evaluated whether exposure to anticholinergic drugs was associated with dementia risk in 58 769 patients with a diagnosis of dementia and 225 574 controls 55 years or older matched by age, sex, general practice, and calendar time.
6 cze 2023 · Memantine is a noncompetitive moderate‐affinity strong voltage‐dependent N‐methyl‐D‐aspartate receptor antagonist. It has been used to treat Alzheimer's disease (AD) since 1989. In 2018, it became the second most commonly used drug for the treatment of dementia in the world.
24 lip 2018 · Our study suggests that memantine has a very small efficacy on AD symptomatology and its safety profile is similar to that of placebo. No evidence of treatment discontinuation improvement with memantine is found, indicating a dubious risk-benefit relationship.
The meta-analyses suggest the credible efficacy and safety of memantine in treating AD when used alone or in combination with ChEIs.
8 mar 2012 · The severity of dementia at entry significantly influenced the effect of donepezil on SMMSE scores, with larger benefits observed in patients with moderate disease (SMMSE score, 10 to 13) than in...
